Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene
Open accessPublished version of a preprint
The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
Trk ( NTRK ) receptor and NTRK gene fusions are oncogenic drivers of a wide variety of tumors. Although Trk receptors are typically activated at the cell surface, signaling of constitutive active Trk and diverse intracellular NTRK fusion oncogenes is barely investigated. Here, we show that a high intracellular abundance is sufficient for neurotrophin-independent, constitutive activation of TrkB kinase domains. In HEK293 cells, constitutive active TrkB kinase and an intracellular NTRK2-fusion oncogene (SQSTM1-NTRK2) reduced actin filopodia dynamics, phosphorylated FAK, and altered the cell morphology. Atypical cellular responses could be mimicked with the intracellular kinase domain, which did not activate the Trk-associated MAPK/ERK pathway. In glioblastoma-like U87MG cells, expression of TrkB or SQSTM1-NTRK2 reduced cell motility and caused drastic changes in the transcriptome. Clinically approved Trk inhibitors or mutating Y 705 in the kinase domain, blocked the cellular effects and transcriptome changes. Atypical signaling was also seen for TrkA and TrkC. Moreover, hallmarks of atypical pTrk kinase were found in biopsies of Nestin-positive glioblastoma. Therefore, we suggest Western blot-like immunoassay screening of NTRK-related (brain) tumor biopsies to identify patients with atypical panTrk or phosphoTrk signals. Such patients could be candidates for treatment with NTRK inhibitors such as Larotrectinhib or Entrectinhib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sustained TrkB activation enhances survival and growth signaling, and Trk family receptors are established oncogenic drivers when aberrantly engaged [135,136,137].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [136]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“The count output was used to identify differentially expressed genes using DESeq2 [51] version 1.24.0.”
InfluentialNIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 1×
“12-bit z-stack images were processed by maximum intensity projection and adjusted for brightness and contrast using Image J software (Rasband, W.S., ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA, https:// imagej.nih.gov/ij/) [47].”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · cited 1×
“7.2b with default parameters based on the RefSeq annotation version 109.20210226 for GRCh38.p13 [49].”
InfluentialCutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · cited 1×
“To ensure high sequence quality, Illumina reads were quality-and adapter-trimmed using Cutadapt [48] version 2.5 using a cutoff Phred score of 20 in the NextSeq mode, and reads without any remaining bases were discarded (command line parameters: --nextseq-trim = 20 -m 1 -a…”
InfluentialfeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
The Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H., & Vilo, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz369 · Cited by 5,045
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856 · cited 2×
“Doxycycline-inducible lentiviral expression of TrkB constructs was performed using a vector backbone based on pCW [41].”
The Reactome Pathway Knowledgebase
Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P., Haw, R., Jassal, B., Korninger, F., May, B., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1132 · Cited by 2,855 · cited 2×
“Cells transduced with the indicated lentiviral constructs were maintained as a polyclonal cell line, and puromycin was used to select transduced cells.”
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537 · cited 3×
“2B, Videos 3 and 4).”
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298 · cited 3×
“2B, Videos 3 and 4).”
Neurotrophin regulation of neural circuit development and function
Park, H., & Poo, M.-M. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3379 · Cited by 2,060 · cited 1×
“Trk receptors play important roles in the development and physiology of the nervous system, neuronal differentiation, and synaptic communication [4 – 6].”
Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors
Lois, C., Hong, E. J., Pease, S., Brown, E. J., & Baltimore, D. (2002) · Science · doi:10.1126/science.1067081 · Cited by 1,999
Cell adhesion: integrating cytoskeletal dynamics and cellular tension
Parsons, J. T., Horwitz, A. R., & Schwartz, M. A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2957 · Cited by 1,988 · cited 2×
“We observed large structural rearrangements between the TrkB model (blue) and activated insulin receptor (green).”
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485 · cited 10×
“This raises the question of how intracellular Trk kinase domains become constitutive active when important protein domains for ER translocation, cell surface transport, ligand binding, dimerization, and kinase activation are missing [12].”
InfluentialActin Dynamics, Architecture, and Mechanics in Cell Motility
Blanchoin, L., Boujemaa-Paterski, R., Sykes, C., & Plastino, J. (2014) · Physiological Reviews · doi:10.1152/physrev.00018.2013 · Cited by 1,457 · cited 1×
“We had a closer look at Y 705 utilizing a TrkB crystal structure (pdb code 4AT4) and asked whether there are unusual structural features in TrkB in comparison to TrkB-YFY or phosphorylated Y 705 .”
The trk proto-oncogene encodes a receptor for nerve growth factor
Klein, R., Jing, S., Nanduri, V., O'Rourke, E., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90419-y · Cited by 1,401 · cited 1×
“The three NTRK genes NTRK1 , NTRK2 , and NTRK3 encode neurotrophin receptors TrkA, TrkB, and TrkC, respectively [2, 3].”
The Trk family of neurotrophin receptors
Barbacid, M. (1994) · Journal of Neurobiology · doi:10.1002/neu.480251107 · Cited by 1,281 · cited 1×
“The three NTRK genes NTRK1 , NTRK2 , and NTRK3 encode neurotrophin receptors TrkA, TrkB, and TrkC, respectively [2, 3].”
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,105 · cited 1×
“Fusions of NTRK1 , NTRK2 , and NTRK3 genes belong to the genomic landscape of diverse types of gliomas [26 – 30].”
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968 · cited 5×
“To better control protein abundance in this cell model, we expressed TrkB-wt, TrkB-YFY, and SQSTM1-NTRK2 using a doxycycline-inducible lentiviral vector [41] (Fig.”
InfluentialKlein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90628-c · Cited by 958 · cited 1×
“2B, Videos 3 and 4).”
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
Martin-Zanca, D., Hughes, S. H., & Barbacid, M. (1986) · Nature · doi:10.1038/319743a0 · Cited by 803 · cited 2×
“Trk was originally discovered as an oncogenic driver in human colon carcinoma [1].”
Brain-derived Neurotrophic Factor Is Stored in Human Platelets and Released by Agonist Stimulation
Fujimura, H., Chen, R., Nakamura, T., Nakahashi, T., Kambayashi, J.-I., Sun, B., Altar, C., & Tandon, N. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613072 · Cited by 777
Middlemas, D. S., Lindberg, R. A., & Hunter, T. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.143 · Cited by 775 · cited 1×
“2B, Videos 3 and 4).”
Reassembly of contractile actin cortex in cell blebs
Charras, G. T., Hu, C.-K., Coughlin, M., & Mitchison, T. J. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200602085 · Cited by 619 · cited 1×
“Furthermore, we tested for phosphorylated co fi lin, a protein involved in F-actin reorganization, and focal adhesion kinase (FAK), a cytosolic tyrosine kinase that regulates focal adhesion site assembly, membrane protrusion formation, and cell motility [61].”
Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB
Douma, S., van Laar, T., Zevenhoven, J., Meuwissen, R., van Garderen, E., & Peeper, D. S. (2004) · Nature · doi:10.1038/nature02765 · Cited by 607
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559 · cited 1×
“To target tumorigenic Trk kinase domains, small-molecule Trk inhibitors have been developed [31].”
Molecular characterization of cancers with NTRK gene fusions
Gatalica, Z., Xiu, J., Swensen, J., & Vranic, S. (2019) · Modern Pathology · doi:10.1038/s41379-018-0118-3 · Cited by 486 · cited 3×
“To better control protein abundance in this cell model, we expressed TrkB-wt, TrkB-YFY, and SQSTM1-NTRK2 using a doxycycline-inducible lentiviral vector [41] (Fig.”
Activation of Trk neurotrophin receptors in the absence of neurotrophins
Lee, F. S., & Chao, M. V. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061020198 · Cited by 482
Origin of the U87MG glioma cell line: Good news and bad news
Allen, M., Bjerke, M., Edlund, H., Nelander, S., & Westermark, B. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6853 · Cited by 466 · cited 2×
“U87MG, a glioblastoma-like cell line [43] (ATCC, Cat# HTB-14) and NIH-3T3 (Cell lines Services, #400101) were cultured in the same medium.”
Drilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0507 · Cited by 439 · cited 1×
“In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.”
Bergami, M., Rimondini, R., Santi, S., Blum, R., Götz, M., & Canossa, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803702105 · Cited by 415 · cited 1×
“As the kinase domain of Trk family members is highly conserved, it is possible that the observed signaling principles hold true for all Trk family members and other kinase fusion proteins.”
Self-citationInteraction Codes within the Family of Mammalian Phox and Bem1p Domain-containing Proteins
Lamark, T., Perander, M., Outzen, H., Kristiansen, K., Øvervatn, A., Michaelsen, E., Bjørkøy, G., & Johansen, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303221200 · Cited by 395 · cited 1×
“S7), arrows in magenta).”
Cazorla, M., Prémont, J., Mann, A., Girard, N., Kellendonk, C., & Rognan, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43992 · Cited by 392 · cited 1×
“2B, Videos 3 and 4).”
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Guerreiro Stucklin, A. S., Ryall, S., Fukuoka, K., Zapotocky, M., Lassaletta, A., Li, C., Bridge, T., Kim, B., Arnoldo, A., Kowalski, P. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12187-5 · Cited by 367
Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells
Rose, C. R., Blum, R., Pichler, B., Lepier, A., Kafitz, K. W., & Konnerth, A. (2003) · Nature · doi:10.1038/nature01983 · Cited by 356 · cited 1×
“2B, Videos 3 and 4).”
Self-citationOkamura, R., Boichard, A., Kato, S., Sicklick, J. K., Bazhenova, L., & Kurzrock, R. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00183 · Cited by 328 · cited 1×
“In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.”
Neurobiology of local and intercellular BDNF signaling
Sasi, M., Vignoli, B., Canossa, M., & Blum, R. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-1964-4 · Cited by 324 · cited 5×
“In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.”
InfluentialSelf-citationTropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
Amatu, A., Sartore-Bianchi, A., Bencardino, K., Pizzutilo, E. G., Tosi, F., & Siena, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz383 · Cited by 309
Polarity proteins in migration and invasion
Etienne-Manneville, S. (2008) · Oncogene · doi:10.1038/onc.2008.347 · Cited by 295 · cited 1×
“Transcripts upregulated by TrkB-wt (log2-fold, padj 0.05) were also found to be upregulated in the SQSTM1-NTRK2 transcript.”
InfluentialWang, X., Prager, B. C., Wu, Q., Kim, L. J. Y., Gimple, R. C., Shi, Y., Yang, K., Morton, A. R., Zhou, W., Zhu, Z., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.03.011 · Cited by 285 · cited 1×
“Constitutive TrkB and TrkC receptor signaling has been associated with tumorigenesis in glioblastoma [23, 24] and TrkB and TrkC signaling is also abundant in glioblastoma, the most common type of brain tumor in adults [25].”
Clarke, M., Mackay, A., Ismer, B., Pickles, J. C., Tatevossian, R. G., Newman, S., Bale, T. A., Stoler, I., Izquierdo, E., Temelso, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1030 · Cited by 271
Identifying patients with NTRK fusion cancer
Solomon, J. P., Benayed, R., Hechtman, J. F., & Ladanyi, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz384 · Cited by 270 · cited 1×
“Furthermore, immunohistochemistry of NTRK-positive tumor samples localized NTRK fusion proteins to other cellular compartments than native Trk receptors [38].”
Zhang, M., Song, T., Yang, L., Chen, R., Wu, L., Yang, Z., & Fang, J. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-85 · Cited by 269
Rajagopal, R., Chen, Z.-Y., Lee, F. S., & Chao, M. V. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0010-04.2004 · Cited by 257
Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not
Nikoletopoulou, V., Lickert, H., Frade, J. M., Rencurel, C., Giallonardo, P., Zhang, L., Bibel, M., & Barde, Y.-A. (2010) · Nature · doi:10.1038/nature09336 · Cited by 216 · cited 1×
“Lentiviral constructs in FuGW carry an N-terminal HA-tag between the signal peptide and the fi rst amino acid of the mature TrkB receptor [42].”
Expression of stem cell markers in human astrocytomas of different WHO grades
Ma, Y.-H., Mentlein, R., Knerlich, F., Kruse, M.-L., Mehdorn, H. M., & Held-Feindt, J. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9439-7 · Cited by 178 · cited 4×
“Recently, in was con fi rmed that patients with SQSTM1-NTRK2 -positive tumors show complete response to Trk-inhibitor therapy with Larotrec-tinhib [62].”
InfluentialTrkA glycosylation regulates receptor localization and activity
Watson, F. L., Porcionatto, M. A., Bhattacharyya, A., Stiles, C. D., & Segal, R. A. (1999) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(199905)39:2<323::aid-neu15>3.0.co;2-4 · Cited by 163 · cited 1×
“In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.”
The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells
Wai, D. H., Knezevich, S. R., Lucas, T., Jansen, B., Kay, R. J., & Sorensen, P. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203396 · Cited by 162 · cited 2×
“…of intracellular NTRK fusion proteins, two mechanisms are plausible: (1) dimerization and transactivation are forced by the fusion domain [12, 39] or (2) abundance-dependent kinase domains undergo autoactivation and become constitutive active, as they do in vitro [18, 19] (discussed in [6]).”
Behaviors of Glioblastoma Cells in in Vitro Microenvironments
Diao, W., Tong, X., Cheng, Y., Zhang, F., Bao, C., Chen, H., Liu, L., Li, M., Ye, F., Fan, Q., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36347-7 · Cited by 160 · cited 1×
“TrkB caused transcriptional reprogramming of U87MG cells by upregulating various immune response genes such as BST2, SERPNG1, IFI27, IDO1, GBP4, KRT17, IFIT2, IFI6, and TNSF10 (Fig.”
Hong, D. S., Bauer, T. M., Lee, J. J., Dowlati, A., Brose, M. S., Farago, A. F., Taylor, M. H., Shaw, A. T., Montez, S., Meric‐Bernstam, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy539 · Cited by 153 · cited 1×
“These tumor-agnostic drugs, e.g. Larotrectinib or Entrectinib, are modern pharmaceuticals for precision oncology and show good response rates to NTRK fusion-positive cancers [12,32 – 36].”
Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum
Naegelin, Y., Dingsdale, H., Säuberli, K., Schädelin, S., Kappos, L., & Barde, Y.-A. (2018) · eneuro · doi:10.1523/eneuro.0419-17.2018 · Cited by 151
Lawn, S., Krishna, N., Pisklakova, A., Qu, X., Fenstermacher, D. A., Fournier, M., Vrionis, F. D., Tran, N., Chan, J. A., Kenchappa, R. S., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.599373 · Cited by 140 · cited 2×
“In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.”
Structural basis of p62/SQSTM1 helical filaments and their role in cellular cargo uptake
Jakobi, A. J., Huber, S. T., Mortensen, S. A., Schultz, S. W., Palara, A., Kuhm, T., Shrestha, B. K., Lamark, T., Hagen, W. J. H., Wilmanns, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14343-8 · Cited by 119
Wiese, S., Jablonka, S., Holtmann, B., Orel, N., Rajagopal, R., Chao, M. V., & Sendtner, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705267104 · Cited by 117
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
Ferguson, S. D., Zhou, S., Huse, J. T., de Groot, J., Xiu, J., Subramaniam, D. S., Mehta, S. V., Gatalica, Z., Swensen, J. J., Sanai, N., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly022 · Cited by 106
Expression of the Neurotrophin Receptor TrkB Is Associated With Unfavorable Outcome in Wilms’ Tumor
Eggert, A., Grotzer, M. A., Ikegaki, N., Zhao, H., Cnaan, A., Brodeur, G. M., & Evans, A. E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.689 · Cited by 104 · cited 1×
“Moreover, Trk kinase overexpression and genomic ampli fi cation of NTRK have been observed in a range of human cancers [12, 22].”
A function–structure model for NGF‐activated TRK
Cunningham, M. E., & Greene, L. A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7282 · Cited by 94 · cited 1×
“Binding of neurotrophins to the extracellular domains of Trk induces receptor dimerization and subsequent trans-autophosphorylation [7 – 11].”
EGF transactivation of Trk receptors regulates the migration of newborn cortical neurons
Puehringer, D., Orel, N., Lüningschrör, P., Subramanian, N., Herrmann, T., Chao, M. V., & Sendtner, M. (2013) · Nature Neuroscience · doi:10.1038/nn.3333 · Cited by 91 · cited 2×
“In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.”
Self-citationDopamine D1 Receptor-induced Signaling through TrkB Receptors in Striatal Neurons
Iwakura, Y., Nawa, H., Sora, I., & Chao, M. V. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801553200 · Cited by 90
Structure and function of p62/SQSTM1 in the emerging framework of phase separation
Berkamp, S., Mostafavi, S., & Sachse, C. (2021) · The FEBS Journal · doi:10.1111/febs.15672 · Cited by 81 · cited 2×
“The most prominent pTrk-kin signal was close to the perinuclear region in Golgi apparatus-like localization.”
An active role for neurons in glioma progression: making sense of Scherer’s structures
Gillespie, S. M., & Monje, M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy083 · Cited by 79 · cited 2×
“In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.”
Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma
Wadhwa, S., Nag, T. C., Jindal, A., Kushwaha, R. C., Mahapatra, A. K., & Sarkar, C. (2003) · Journal of Biosciences · doi:10.1007/bf02706217 · Cited by 71 · cited 1×
“Constitutive TrkB and TrkC receptor signaling has been associated with tumorigenesis in glioblastoma [23, 24] and TrkB and TrkC signaling is also abundant in glioblastoma, the most common type of brain tumor in adults [25].”
Neurotrophin signalling in the human nervous system
Ateaque, S., Merkouris, S., & Barde, Y. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1225373 · Cited by 49
Franco, M. L., Nadezhdin, K. D., Goncharuk, S. A., Mineev, K. S., Arseniev, A. S., & Vilar, M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011312 · Cited by 44 · cited 1×
“In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.”
BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor
Tao, W., Lin, H., Sun, T., Samanta, A. K., & Arlinghaus, R. B. (2007) · Oncogene · doi:10.1038/sj.onc.1210979 · Cited by 34
Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene
Alvarez, A. A., Barisone, G. A., & Díaz, E. (2014) · Journal of Visualized Experiments · doi:10.3791/51742 · Cited by 29 · cited 1×
“Cell transformation in NIH-3T3 cells was performed by testing the morphological transformation of adherent NIH-3T3 cells [45, 46].”
DeWitt, J., Ochoa, V., Urschitz, J., Elston, M., Moisyadi, S., & Nishi, R. (2013) · Oncogene · doi:10.1038/onc.2013.39 · Cited by 27
Götz, R., & Sendtner, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100944 · Cited by 26 · cited 1×
“In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.”
Iannantuono, G. M., Riondino, S., Sganga, S., Rosenfeld, R., Guerriero, S., Carlucci, M., Capotondi, B., Torino, F., & Roselli, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111819 · Cited by 25
Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma
Polat, B., Wohlleben, G., Kosmala, R., Lisowski, D., Mantel, F., Lewitzki, V., Löhr, M., Blum, R., Herud, P., Flentje, M. P., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02510-4 · Cited by 24 · cited 2×
“Importantly, effects downstream of active kinase domains are effectively blocked by clinically approved Trk kinase inhibitors, like Larotrectinhib or Entrectin-hib.”
Self-citationSequential Cis/Trans Autophosphorylation in TrkB Tyrosine Kinase
Iwasaki, Y., Nishiyama, H., Suzuki, K., & Koizumi, S. (1997) · Biochemistry · doi:10.1021/bi962057x · Cited by 19
Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB
Artim, S. C., Kiyatkin, A. B., & Lemmon, M. A. (2020) · Biochemical Journal · doi:10.1042/bcj20200695 · Cited by 18 · cited 3×
“…of intracellular NTRK fusion proteins, two mechanisms are plausible: (1) dimerization and transactivation are forced by the fusion domain [12, 39] or (2) abundance-dependent kinase domains undergo autoactivation and become constitutive active, as they do in vitro [18, 19] (discussed in [6]).”
Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma
Pinheiro, K. V., Thomaz, A., Souza, B. K., Metcalfe, V. A., Freire, N. H., Brunetto, A. T., de Farias, C. B., Jaeger, M. D. C., Bambini-Júnior, V., Smith, C. G., et al. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05739-2 · Cited by 11 · cited 1×
“In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.”
Effects of the thalamus on the development of cerebral cortical efferentsin vitro
Lotto, R. B., Aitkenhead, A., & Price, D. J. (1999) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(199905)39:2<186::aid-neu3>3.0.co;2-g · Cited by 7
Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
Frehner, L., Haefliger, S., Cerciello, F., Grob, T. J., & Schmid, S. (2023) · Case Reports in Oncology · doi:10.1159/000533572 · Cited by 6 · cited 1×
“However, induction of expression with 1 μg/ml doxycycline for 48 h led to the constitutive activation of TrkB or SQSTM1-NTRK2 (Figs.”
(1992) · PubMed
Cited by
Lei, P., & Li, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1666343 · Cited by 5
Федотчева, Т. А., & Shimanovsky, N. L. (2025) · Medical Sciences · doi:10.3390/medsci14010015 · Cited by 6
Rahm, K. K., Kinghorn, B. S., Moody, M. J., Stone, B. C., Strong, K., Kim, B. S., Chang, Y. J., Sleight, S., Nitz, A. A., Hansen, D. V., et al. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1681811 · Cited by 5
“…the creation of two classifiers, a primary cell classifier and cell-line classifier, we tested RNA-seq data generated from many different studies (Gupta et al., 2024; Schirmer et al., 2019; Masuda et al., 2019; Quiroga et al., 2022; Armanville et al., 2025; Baek and Yoo, 2021; Baek et al.,…”
Jastrząb, P., Car, H., & Wielgat, P. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117921 · Cited by 4
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Metadata
- Authors
- Gupta, R., Dittmeier, M., Wohlleben, G., Nickl, V., Bischler, T., Luzak, V., Wegat, V., Doll, D., Sodmann, A., Bady, E., Langlhofer, G., Wachter, B., Havlicek, S., Gupta, J., Horn, E., Lüningschrör, P., Villmann, C., Polat, B., Wischhusen, J., Monoranu, C. M., Kuper, J., & Blum, R.
- Affiliations
- Universitätsklinikum Würzburg (DE)
- University of Würzburg (DE)
- Fraunhofer Institute for Interfacial Engineering and Biotechnology (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Corresponding author
- Blum, Robert
- ORCID
- Venue
- Cancer Gene Therapy
- Published
- 2024-07-22
- Volume
- 31
- Issue
- 9
- Pages
- 1357-1379
- ISSN
- 0929-1903 (ISSN-L)
- 1476-5500
- PMC
- PMC11405271
- OpenAlex
- W4400896163
- Cited by
- 7
- References
- 82
- Citations by year
- 2026: 2 · 2025: 5
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer Gene Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
- PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
- Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (project-ID: 194101929 (BL567/3-2), project ID: 326998133; CRC TRR225 (B01))
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (project Z-6, B-450)
- Evangelisches Studienwerk Villigst
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Keywords
- TrkB, NTRK2, constitutive kinase activation, focal adhesion kinase phosphorylation, cell morphology, cell motility, glioblastoma, TrkA, TrkC, TRK inhibitors, larotrectinib, entrectinib, transcriptome changes
- MeSH terms
- Cell Movement, Glioblastoma, Humans, Membrane Glycoproteins, Signal Transduction, Oncogene Proteins, Fusion, Receptor, trkB, Cell Line, Tumor, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.